Abstract: The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface asialoglycoprotein receptor (ASGPR). The cell surface ASGPR binding compounds can trigger the receptor to internalize into the cell a bound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor ASGPR. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided herein methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.

Abstract: The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface asialoglycoprotein receptor (ASGPR). The cell surface ASGPR binding compounds can trigger the receptor to internalize into the cell a bound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor ASGPR. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided herein methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.

Abstract: The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface mannose-6-phosphate receptor (M6PR). The M6PR binding compounds can trigger the receptor to internalize into the cell a bound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the M6PR. Also provided are compound that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific target proteins from the cell surface or the extracellular milieu. For example, the conjugates described herein may sequester and/or degrade a target molecule of interest in a cell's lysosome. Also provided are methods of using the conjugates to target a protein for sequestration and/or lysosomal degradation.

Abstract: A duplex visual tester for testing multiple fiber optic cable runs includes a housing having a first LED and a second LED in a duplex fiber connection. The first LED and the second LED are in electronic communication with a power source, a battery, an on/off switch, and a timer configured to pulse the first LED and the second LED. The first LED and the second LED are installed in the duplex fiber connection. The first LED has a first color, and the second LED has a second, different color, wherein the first color and the second color have the same luminosity. Preferably, the timer pulses the first LED and the second LED at between eight and ten Hz, such that the first color and second color can be seen in the fiber optic cable run.

Abstract: The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface receptor, such as a folate receptor. The cell surface folate binding compound can trigger the receptor to internalize into the cell a bound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor, e.g., folate receptor. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided herein are methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.

Abstract: The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface asialoglycoprotein receptor (ASGPR). The cell surface ASGPR binding compounds can trigger the receptor to internalize into the cell a bound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor ASGPR. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided herein methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.

Abstract: The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface receptor, such as a mannose-6-phosphate receptor (M6PR) or a cell surface asialoglycoprotein receptor (ASGPR). The cell surface M6PR or ASGPR binding compounds can trigger the receptor to internalize into the cell abound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor, e.g., M6PR or ASGPR. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided are methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.

Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Embodiments of the present disclosure relate to providing electronic survey content to a user in accordance with a particular layout. In particular, a survey system facilitates providing survey questions of an electronic survey to a user within a display area of a client device in accordance with a determined layout based on one or more features of the display area. For example, the survey system associates a plurality of layouts with one or more survey questions. Further, the survey system provides the survey questions and associated layout to a client device for presentation to a user. The client device identifies one or more features of a display area and determines a layout from the plurality of layouts to use in providing the survey question(s) to the user. Further, the client device provides one or more survey questions to a user within the display area in accordance with a determined layout.

Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Embodiments of the present disclosure relate to providing electronic survey content to a user in accordance with a particular layout. In particular, a survey system facilitates providing survey questions of an electronic survey to a user within a display area of a client device in accordance with a determined layout based on one or more features of the display area. For example, the survey system associates a plurality of layouts with one or more survey questions. Further, the survey system provides the survey questions and associated layout to a client device for presentation to a user. The client device identifies one or more features of a display area and determines a layout from the plurality of layouts to use in providing the survey question(s) to the user. Further, the client device provides one or more survey questions to a user within the display area in accordance with a determined layout.

Abstract: Embodiments of the present disclosure relate to providing electronic survey content to a user in accordance with a particular layout. In particular, a survey system facilitates providing survey questions of an electronic survey to a user within a display area of a client device in accordance with a determined layout based on one or more features of the display area. For example, the survey system associates a plurality of layouts with one or more survey questions. Further, the survey system provides the survey questions and associated layout to a client device for presentation to a user. The client device identifies one or more features of a display area and determines a layout from the plurality of layouts to use in providing the survey question(s) to the user. Further, the client device provides one or more survey questions to a user within the display area in accordance with a determined layout.

Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Embodiments of the present disclosure relate to providing electronic survey content to a user in accordance with a particular layout. In particular, a survey system facilitates providing survey questions of an electronic survey to a user within a display area of a client device in accordance with a determined layout based on one or more features of the display area. For example, the survey system associates a plurality of layouts with one or more survey questions. Further, the survey system provides the survey questions and associated layout to a client device for presentation to a user. The client device identifies one or more features of a display area and determines a layout from the plurality of layouts to use in providing the survey question(s) to the user. Further, the client device provides one or more survey questions to a user within the display area in accordance with a determined layout.

Abstract: The present invention relates to steganographic encoding for multimedia content. In one combination, a method is provided including: encoding first information in a first component of a multimedia signal, the first component comprising audio, the first information being encoded though subtle changes to data representing the first component; encoding second information in a second component of the multimedia signal, the second component comprising video, the first information being encoded though subtle changes to data representing the first component, the first information and the second information are associated. Of course, other combinations are provided as well.

Abstract: The present invention relates generally to pre-processing images, audio and/or video to improve biometric analysis from such. In one implementation, a method is provided including: receiving a color digital image including a representation of a human subject; converting the color digital image into grayscale values; transforming at least one representation of the converted color image; analyzing the transformed, converted color image to identify artifacts; if artifacts are found, processing the color digital image to reduce the artifacts; and providing the processed digital image to a biometric system. Other implementations are provided as well.

Abstract: A watermarked signal is pre-filtered based on an analysis of signal characteristics that identify filter parameters that yield better correspondence between the filtered watermarked signal and the digital watermark. The watermark detection method computes signal characteristics of a host digitally watermarked signal, and analyzes the characteristics to determine an extent to which the signal characteristics correspond to characteristics of the digital watermark. The method adapts parameters of digital watermark prediction applied to the watermarked signal based on the extent to which the signal characteristics correspond to the characteristics of the digital watermark. In one embodiment, different filters or filter parameters are selected to match different signal characteristics of the watermarked signal with the characteristics of the digital watermark.

Abstract: Directional albedo of a particular article, such as an identity card, is measured and stored. When the article is later presented, it can be confirmed to be the same particular article by re-measuring the albedo function, and checking for correspondence against the earlier-stored data. The re-measuring can be performed through us of a handheld optical device, such as a camera-equipped cell phone. The albedo function can serve as random key data in a variety of cryptographic applications. The function can be changed during the life of the article. A variety of other features are also detailed.